AVROBIO is a biotechnology business based in the US. AVROBIO shares (AVRO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.12 – a decrease of 91.84% over the previous week. AVROBIO employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.12 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $16.17 |
| 200-day moving average | $16.46 |
| Wall St. target price | $2.00 |
| PE ratio | 0.1691 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $8.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.42 from 2024-06-18
| 1 week (2024-10-06) | N/A |
|---|---|
| 1 month (2024-09-13) | N/A |
| 3 months (2024-07-13) | N/A |
| 6 months (2024-04-17) | 16.39% |
| 1 year (2023-10-17) | -10.69% |
|---|---|
| 2 years (2022-10-17) | 133.86% |
| 3 years (2021-10-13) | N/A |
| 5 years (2019-10-17) | 14.02 |
Valuing AVROBIO stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AVROBIO's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AVROBIO's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, AVROBIO shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -35.18% |
| Return on equity TTM | 42.73% |
| Profit margin | 0% |
| Book value | $23.75 |
| Market Capitalization | $5.2 million |
TTM: trailing 12 months
We're not expecting AVROBIO to pay a dividend over the next 12 months.
AVROBIO's shares were split on a 1:12 basis on 20 June 2024. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVROBIO shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for AVROBIO shares which in turn could have impacted AVROBIO's share price.
Over the last 12 months, AVROBIO's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVROBIO's is 1.223. This would suggest that AVROBIO's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
AVROBIO, Inc. , a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.